全球体型雕塑治疗市场:按技术、性别、应用、最终用户、地区划分 - 预测至 2029 年
市场调查报告书
商品编码
1574331

全球体型雕塑治疗市场:按技术、性别、应用、最终用户、地区划分 - 预测至 2029 年

Body Contouring Treatments Market by Product (System (CT, MRI, Angiography, Mammo), Consumable, Accessories), Type (Single & Dual-head, Syringeless), Application (General Imaging, Interventional), and End user - Global Forecast to 2029

出版日期: | 出版商: MarketsandMarkets | 英文 262 Pages | 订单完成后即时交付

价格

全球体型雕塑治疗市场规模预计将从2024年的14.6亿美元增加到2029年的25.8亿美元,2024年至2029年的复合年增长率为10.0%。

人们对整容手术的接受度不断提高,加上个人化和灵活的资金筹措计划,正在推动对这些产品的需求。老化人口中对抗老化治疗的兴趣日益浓厚。体型雕塑手术可以帮助塑造您的身材并提高您的自信心。此外,微创和非侵入性身体轮廓手术的好处不断增加,正在推动对体型雕塑治疗市场的需求。

调查范围
调查年份 2022-2029
基准年 2023年
预测期 2024-2029
考虑单位 金额(美元)
按细分市场 按科技、性别、应用、最终用户、地区
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东/非洲

依技术划分,体型雕塑治疗市场分为侵入式技术和非侵入式技术。 2023 年,非侵入式技术占据主要份额。技术创新的增加、广告的增加以及切口更少的设备的采用的增加预计将推动该细分市场的成长。非侵入性身体轮廓治疗,包括射频、超音波、冷冻溶脂(冷冻脂肪)和雷射技术,在安全性和有效性方面已显着提高。这些技术具有广泛的好处,这就是为什么非侵入性治疗在个人中如此受欢迎的原因。

依应用划分,体型雕塑治疗市场可分为腹部整形、抽脂、非侵入性减脂、橘皮组织治疗等应用。美容中心数量的增加和采用率的提高将推动市场的发展,这主要是由于准确性的提高和效果的改善。非手术减脂治疗在所有类型和年龄的患者中越来越受欢迎。因此,采用创新技术的治疗方法的广泛接受支持了需求的激增,进一步推动了非手术减脂领域的成长。

该报告研究了全球体型雕塑治疗市场,包括按技术、性别、应用、最终用户、地区和参与市场的公司概况分類的趋势。

目录

第一章简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

第五章市场概况

  • 介绍
  • 市场动态
  • 价值链分析
  • 供应链分析
  • 生态系分析
  • 监管状况
  • 赎回场景分析
  • 投资金筹措场景
  • 价格分析
  • 贸易分析
  • 专利分析
  • 波特五力分析
  • 主要相关人员和采购标准
  • 2024-2025年重大会议和活动
  • 案例研究分析
  • 技术分析
  • 影响客户业务的趋势/干扰
  • 未满足的需求
  • 人工智慧/产生人工智慧对体型雕塑治疗市场的影响

第六章体型雕塑治疗市场(依技术)

  • 介绍
  • 侵入性技术
  • 非侵入性技术

第七章体型雕塑治疗市场(性别)

  • 介绍
  • 女病人
  • 男性患者

第八章体型雕塑治疗市场(依应用)

  • 介绍
  • 非手术消脂
  • 去除橘皮组织
  • 抽脂手术
  • 腹部手术
  • 其他的

第九章体型雕塑治疗市场(依最终用户)

  • 介绍
  • 医院
  • 美容诊所
  • 医疗水疗/美容中心

第十章体型雕塑治疗市场(按地区)

  • 介绍
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第十一章竞争格局

  • 概述
  • 主要参与企业的策略/秘密
  • 2019-2023 年收益占有率分析
  • 2023 年市场占有率分析
  • 企业评估矩阵:主要参与企业,2023
  • 企业评估矩阵:Start-Ups/小型企业,2023 年
  • 企业价值评估及财务指标
  • 品牌/产品比较
  • 竞争场景

第十二章 公司简介

  • 主要参与企业
    • ABBVIE INC.
    • INMODE LTD.
    • BAUSCH HEALTH COMPANIES INC.
    • CYNOSURE LUTRONIC
    • SISRAM MEDICAL LTD
    • CUTERA, INC.
    • EL.EN. SPA
    • VENUS CONCEPT
    • SHARPLIGHT TECHNOLOGIES INC.
    • SCITON
    • CANDELA CORPORATION
    • BTL INDUSTRIES
    • FOTONA
    • GZ MTS ELECTRONICS CO., LTD.
    • ROHRER AESTHETICS, INC.
  • 其他公司
    • GBS INTERNATIONAL HOLDING LTD.
    • SINCLAIR
    • THERMI
    • YOLO MEDICAL INC.
    • DOMINION AESTHETIC TECHNOLOGIES, INC.
    • ZIMMER MEDIZIN SYSTEME GMBH
    • ERCHONIA CORPORATION
    • CLASSYS INC.
    • WON TECH CO., LTD.
    • CELLSOUND AESTHETICS

第十三章附录

Product Code: MD 9199

The global body contouring treatments market is expected to reach USD 2.58 billion by 2029 from USD 1.46 billion in 2024, at a CAGR of 10.0% from 2024 to 2029. Increase in acceptance of aesthetic procedures, coupled with personalized and flexible financing plans has increased the demand for these products. Growing interest in anti-aging procedures are more prevalent in aging population. Body contouring procedures helps to reshape and improvesconfidence. Moreover,increased benefits of minimally invasive and non-invasive body contouring procedures have driven demand for body contouring treatments market.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD)
SegmentsBy Technology, patient type, application, end user, and region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

"The non-invasive technologies segment of technology segment held the largest share of the market in 2023"

The body contouring treatments market is segmented based on technology into invasive technologies and non-invasive technologies. The non-invasive technologies accounted for a major share in 2023. Increase in technological innovations, rise in advertisement, and the rising adoption of devices due to less incisions is anticipated to fuel the growth of the segment. Treatments for non-invasive body contouring that involve radiofrequency, ultrasound, cryolipolysis (freezing fat), and laser-based techniques have significantly improved in tems of safety and effectiveness. These technologies have a wide range of benefits, which contribute to the non-invasive treatment popularity among individuals.

"The non-surgical fat reduction segment of application segment held the largest share of the market in 2023"

The body contouring treatments market can be segmented based on application into abdominoplasty, liposuction, non-invasive fat reduction, cellulite treatment, and other applications. Increasing number of beauty centers and rising adoption mainly due to improved accuracy and better outcomes drives the market. The non-surgical fat reduction treatments are gaining popularity across all patient types and ages. Hence, broader acceptance for treatment procedures due to innovative technologies supports the surge in demand that further drives the growth for the non-surgical fat reduction segment.

"The female patients segment for patient type segment to hold the largest market share in 2023".

Based on patient type , the body contouring treatments market is segmented into female patients and male patients. Female patients is the major segment, accounting for the largest body contouring treatments market share in 2023. The increase in awareness about non-invasive body contouring procedures, rise in post-pregnancy body reconstruction procedures, increase in influencer endorsements, and social media promotion supports the growth of the segment.

"The aesthetic clinics segment for the end user segment is projected to register a significant CAGR during the forecast period."

The body contouring treatments market is segmented by end-users into hospitals, aesthetic clinics, and medical spas & beauty centers. The hospitals accounted for a major end-user market share in 2023. The increase in spending on body shaping procedures and rise in medical tourism, and rising disposable income per capita is anticipated to propel the segment growth. Furthermore, rising adoption of new and improved devices in the hopsitals is expected to support the growth of this segment.

"The market in the Asia Pacific region is expected to witness the highest growth during the forecast period."

The north america region accounted for major share in 2023. Asia pacific region to grow at the highest CAGR in body contouring treatments market. Healthcare infrastructure and service investments, especially in the emerging economies, are fostering the development of medical aesthetics, which leads to growing demand for body contouring. In this regard, market leaders have increased their efforts to strengthen their presence in the Asia Pacific market to meet the ever-growing requirement for body contouring treatment. The availability and accessibility of the service in this market have also been enhanced by the increasing presence of aesthetic clinics, particularly in the APAC region.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1-30%, Tier 2-42%, and Tier 3- 28%
  • By Designation: Director-level-10%, C-level-14%, and Others-76%
  • By Region: North America-40%, Europe-30%, Asia Pacific-22%, Latin America-6%, and RoW- 10%

The prominent players in the body contouring treatments market are as AbbVie Inc. (US), InMode Ltd. (Israel), Bausch Health Companies Inc. (Canada), Cynosure Lutronic (US), Venus Concept (Canada), EL.EN.S.P.A (Italy), Sisram Medical Ltd. (Israel), BTL Industries(UK), Sharplight Technologies Inc. (Canada), Sciton Inc. (US), Candela Corporation (US), Fotona (Solvenia )

The study includes as in-depth competitive analysis of these key players in the authentication and brand protection market, with their company profiles recent developments,and key market stratergies

Research Coverage

This report studies the body contouring treatments market based on technology, application, patient type, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will help market leaders and new entrants with information on the closest approximations of the revenue numbers for the overall body contouring treatments market and the subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

This report provides insights on the following pointers:

  • Analysis of key drivers (Growing adoption for minimally invasive and non-invasive body contouring procedure, increasing demand for aesthetic treatments among men, rising adoption of new and innovative body contouring technologies , broad acceptance of aesthetic procedure and growing attention on appearance and body image), restraints (high cost of treatment and inadequate reimbursement policies), opportunities (growth potential in emerging economies), and challenges (social and cultural barrriers in emerging economies, stringent regulatory compliance and safety standards) influencing the growth of the body contouring treatments market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the body contouring treatments market
  • Market Development: Comprehensive information about lucrative markets-the report analyses the body contouring treatments market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the body contouring treatments market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players, such as AbbVie Inc. (US), Inmode Ltd. (Israel), Bausch Health Companies Inc. (Canada), Cynosure Lutronic (US), Sisram Medical Ltd (Israel)

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 INCLUSIONS AND EXCLUSIONS
  • 1.4 STUDY SCOPE
    • 1.4.1 MARKETS COVERED
    • 1.4.2 YEARS CONSIDERED
    • 1.4.3 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 IMPACT OF AI/GEN AI

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key sources for secondary research
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key primary sources
      • 2.1.2.2 Key industry insights
      • 2.1.2.3 Breakdown of primary interviews
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Company revenue estimation approach
      • 2.2.1.2 Customer-based market estimation
      • 2.2.1.3 Growth forecast approach
      • 2.2.1.4 CAGR projections
  • 2.3 DATA TRIANGULATION
  • 2.4 MARKET SHARE ANALYSIS
  • 2.5 RESEARCH ASSUMPTIONS
    • 2.5.1 PARAMETRIC ASSUMPTIONS
    • 2.5.2 GROWTH RATE ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 BODY CONTOURING TREATMENTS MARKET OVERVIEW
  • 4.2 NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY
  • 4.3 ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET, BY END USER
  • 4.4 EUROPE: BODY CONTOURING TREATMENTS MARKET, BY APPLICATION
  • 4.5 GEOGRAPHIC SNAPSHOT OF BODY CONTOURING TREATMENTS MARKET

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing adoption of minimally invasive and non-invasive body contouring procedures
      • 5.2.1.2 Increasing demand for aesthetic treatments among men
      • 5.2.1.3 Rising adoption of new and innovative body contouring technologies
      • 5.2.1.4 Widespread social media influence and cultural changes
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of treatment and inadequate reimbursement policies
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growth potential in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Social and cultural barriers
      • 5.2.4.2 Stringent regulatory compliance and safety standards
  • 5.3 VALUE CHAIN ANALYSIS
    • 5.3.1 RESEARCH & PRODUCT DEVELOPMENT
    • 5.3.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING
    • 5.3.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
  • 5.4 SUPPLY CHAIN ANALYSIS
    • 5.4.1 MANUFACTURERS
      • 5.4.1.1 Prominent companies
      • 5.4.1.2 Small and medium-sized enterprises
    • 5.4.2 END USERS
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 REGULATORY LANDSCAPE
    • 5.6.1 REGULATORY ANALYSIS
      • 5.6.1.1 North America
        • 5.6.1.1.1 US
        • 5.6.1.1.2 Canada
      • 5.6.1.2 Europe
      • 5.6.1.3 Asia Pacific
        • 5.6.1.3.1 Japan
        • 5.6.1.3.2 China
        • 5.6.1.3.3 India
      • 5.6.1.4 Latin America
        • 5.6.1.4.1 Brazil
    • 5.6.2 REGULATORY APPROVALS
    • 5.6.3 KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.7 REIMBURSEMENT SCENARIO ANALYSIS
  • 5.8 INVESTMENT AND FUNDING SCENARIO
  • 5.9 PRICING ANALYSIS
    • 5.9.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY TECHNOLOGY
    • 5.9.2 AVERAGE SELLING PRICE TREND OF BODY CONTOURING DEVICES, BY REGION
  • 5.10 TRADE ANALYSIS
    • 5.10.1 IMPORT DATA
    • 5.10.2 EXPORT DATA
  • 5.11 PATENT ANALYSIS
  • 5.12 PORTER'S FIVE FORCES ANALYSIS
    • 5.12.1 THREAT OF NEW ENTRANTS
    • 5.12.2 THREAT OF SUBSTITUTES
    • 5.12.3 BARGAINING POWER OF SUPPLIERS
    • 5.12.4 BARGAINING POWER OF BUYERS
    • 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.13.2 KEY BUYING CRITERIA
  • 5.14 KEY CONFERENCES AND EVENTS, 2024-2025
  • 5.15 CASE STUDY ANALYSIS
    • 5.15.1 IMPROVED FAT REDUCTION PROCEDURES USING LARGER APPLICATOR
    • 5.15.2 ENHANCED SUPPLY CHAIN AND OPERATIONAL EFFICIENCY WITH HIGHER RESEARCH & DEVELOPMENT
  • 5.16 TECHNOLOGY ANALYSIS
    • 5.16.1 KEY TECHNOLOGIES
      • 5.16.1.1 Thermal technologies
      • 5.16.1.2 Non-thermal technologies
    • 5.16.2 COMPLEMENTARY TECHNOLOGIES
      • 5.16.2.1 Skin cooling systems
    • 5.16.3 ADJACENT TECHNOLOGIES
      • 5.16.3.1 Treatment planning software
  • 5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.18 UNMET NEEDS
  • 5.19 IMPACT OF AI/GEN AI ON BODY CONTOURING TREATMENTS MARKET
    • 5.19.1 KEY USE CASES

6 BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY

  • 6.1 INTRODUCTION
  • 6.2 INVASIVE TECHNOLOGIES
    • 6.2.1 INVASIVE RADIOFREQUENCY TECHNOLOGY
      • 6.2.1.1 Growing inclination toward skin tightening to propel market
    • 6.2.2 INVASIVE LASER TECHNOLOGY
      • 6.2.2.1 Higher advantages compared to traditional techniques to speed up growth
    • 6.2.3 INVASIVE ULTRASOUND TECHNOLOGY
      • 6.2.3.1 Targeted fat reduction and minimal discomfort to augment growth
  • 6.3 NON-INVASIVE TECHNOLOGIES
    • 6.3.1 NON-INVASIVE RADIOFREQUENCY TECHNOLOGY
      • 6.3.1.1 Rising use of cellulite treatment, fat reduction, and skin tightening to drive market
    • 6.3.2 NON-INVASIVE LASER TECHNOLOGY
      • 6.3.2.1 Growing adoption in hospitals and aesthetic clinics to fuel market
    • 6.3.3 NON-INVASIVE ULTRASOUND TECHNOLOGY
      • 6.3.3.1 Need for precise temperature management control to accelerate growth
    • 6.3.4 CRYOLIPOLYSIS TECHNOLOGY
      • 6.3.4.1 Low risk and minimal side effects to facilitate growth
    • 6.3.5 OTHER NON-INVASIVE TECHNOLOGIES

7 BODY CONTOURING TREATMENTS MARKET, BY GENDER

  • 7.1 INTRODUCTION
  • 7.2 FEMALE PATIENTS
    • 7.2.1 GROWING USE OF BODY CONTOURING TO ADDRESS POST-SURGICAL CHANGES TO BOOST MARKET
  • 7.3 MALE PATIENTS
    • 7.3.1 INCREASING SHIFT IN SOCIAL AND AESTHETIC STANDARDS TO EXPEDITE GROWTH

8 BODY CONTOURING TREATMENTS MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 NON-SURGICAL FAT REDUCTION
    • 8.2.1 GROWING PREFERENCE FOR MINIMALLY INVASIVE PROCEDURES TO FUEL MARKET
  • 8.3 CELLULITE REDUCTION
    • 8.3.1 RISING OBESITY RATES TO SUPPORT MARKET GROWTH
  • 8.4 LIPOSUCTION
    • 8.4.1 GROWING DEMAND FOR COSMETIC ENHANCEMENT WITH SHORTER RECOVERY TIMES TO DRIVE MARKET
  • 8.5 ABDOMINOPLASTY
    • 8.5.1 INCREASING DESIRE FOR AESTHETIC IMPROVEMENTS TO PROMOTE GROWTH
  • 8.6 OTHER APPLICATIONS

9 BODY CONTOURING TREATMENTS MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 HOSPITALS
    • 9.2.1 BOOMING MEDICAL TOURISM TO CONTRIBUTE TO MARKET GROWTH
  • 9.3 AESTHETIC CLINICS
    • 9.3.1 GROWING ESTABLISHMENT OF SPECIALTY CLINICS TO DRIVE MARKET
  • 9.4 MEDICAL SPAS & BEAUTY CENTERS
    • 9.4.1 RISING FOCUS ON BODY APPEARANCE TO AID GROWTH

10 BODY CONTOURING TREATMENTS MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 10.2.2 US
      • 10.2.2.1 Growing public acceptance of body contouring procedures to drive market
    • 10.2.3 CANADA
      • 10.2.3.1 Rising inclination toward reducing signs of aging to aid growth
  • 10.3 EUROPE
    • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 10.3.2 GERMANY
      • 10.3.2.1 Increasing volume of aesthetic procedures to drive market
    • 10.3.3 FRANCE
      • 10.3.3.1 Increasing demand for age-related aesthetic treatments to spur growth
    • 10.3.4 UK
      • 10.3.4.1 Rising focus of men on body aesthetics to encourage growth
    • 10.3.5 ITALY
      • 10.3.5.1 Gowing adoption of surgical procedures among young females to boost market
    • 10.3.6 SPAIN
      • 10.3.6.1 Growing availability of high-quality and effective products to fuel market
    • 10.3.7 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 10.4.2 JAPAN
      • 10.4.2.1 Presence of medical aesthetic associations to spur growth
    • 10.4.3 CHINA
      • 10.4.3.1 Increased availability of cosmetic surgery apps and online services to support growth
    • 10.4.4 INDIA
      • 10.4.4.1 Increasing disposable income to contribute to market growth
    • 10.4.5 AUSTRALIA
      • 10.4.5.1 Favorable government initiatives to promote growth
    • 10.4.6 SOUTH KOREA
      • 10.4.6.1 Rising influx of foreign patients to facilitate growth
    • 10.4.7 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 10.5.2 BRAZIL
      • 10.5.2.1 Heightened awareness regarding body contouring enhancements to stimulate growth
    • 10.5.3 MEXICO
      • 10.5.3.1 Increase in patient inflow from US to sustain growth
    • 10.5.4 REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 GROWING AVAILABILITY OF HIGH-QUALITY TREATMENTS TO DRIVE MARKET
    • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BODY CONTOURING TREATMENTS MARKET
  • 11.3 REVENUE SHARE ANALYSIS, 2019-2023
  • 11.4 MARKET SHARE ANALYSIS, 2023
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 11.5.5.1 Company footprint
      • 11.5.5.2 Technology footprint
      • 11.5.5.3 Gender footprint
      • 11.5.5.4 Application footprint
      • 11.5.5.5 End-user footprint
      • 11.5.5.6 Region footprint
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 RESPONSIVE COMPANIES
    • 11.6.3 DYNAMIC COMPANIES
    • 11.6.4 STARTING BLOCKS
    • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 11.7 COMPANY VALUATION AND FINANCIAL METRICS
    • 11.7.1 COMPANY VALUATION
    • 11.7.2 FINANCIAL METRICS
  • 11.8 BRAND/PRODUCT COMPARISON
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 PRODUCT LAUNCHES AND APPROVALS
    • 11.9.2 DEALS
    • 11.9.3 EXPANSIONS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
    • 12.1.1 ABBVIE INC.
      • 12.1.1.1 Business overview
      • 12.1.1.2 Products offered
      • 12.1.1.3 Recent developments
        • 12.1.1.3.1 Product launches and approvals
      • 12.1.1.4 MnM view
        • 12.1.1.4.1 Key strengths
        • 12.1.1.4.2 Strategic choices
        • 12.1.1.4.3 Weaknesses and competitive threats
    • 12.1.2 INMODE LTD.
      • 12.1.2.1 Business overview
      • 12.1.2.2 Products offered
      • 12.1.2.3 Recent developments
        • 12.1.2.3.1 Product launches and approvals
        • 12.1.2.3.2 Deals
      • 12.1.2.4 MnM view
        • 12.1.2.4.1 Key strengths
        • 12.1.2.4.2 Strategic choices
        • 12.1.2.4.3 Weaknesses and competitive threats
    • 12.1.3 BAUSCH HEALTH COMPANIES INC.
      • 12.1.3.1 Business overview
      • 12.1.3.2 Products offered
      • 12.1.3.3 Recent developments
        • 12.1.3.3.1 Product launches and approvals
      • 12.1.3.4 MnM view
        • 12.1.3.4.1 Key strengths
        • 12.1.3.4.2 Strategic choices
        • 12.1.3.4.3 Weaknesses and competitive threats
    • 12.1.4 CYNOSURE LUTRONIC
      • 12.1.4.1 Business overview
      • 12.1.4.2 Products offered
      • 12.1.4.3 Recent developments
        • 12.1.4.3.1 Deals
      • 12.1.4.4 MnM view
        • 12.1.4.4.1 Key strengths
        • 12.1.4.4.2 Strategic choices
        • 12.1.4.4.3 Weaknesses and competitive threats
    • 12.1.5 SISRAM MEDICAL LTD
      • 12.1.5.1 Business overview
      • 12.1.5.2 Products offered
      • 12.1.5.3 Recent developments
        • 12.1.5.3.1 Product launches and approvals
        • 12.1.5.3.2 Deals
        • 12.1.5.3.3 Expansions
      • 12.1.5.4 MnM view
        • 12.1.5.4.1 Key strengths
        • 12.1.5.4.2 Strategic choices
        • 12.1.5.4.3 Weaknesses and competitive threats
    • 12.1.6 CUTERA, INC.
      • 12.1.6.1 Business overview
      • 12.1.6.2 Products offered
      • 12.1.6.3 Recent developments
        • 12.1.6.3.1 Product launches and approvals
    • 12.1.7 EL.EN. S.P.A.
      • 12.1.7.1 Business overview
      • 12.1.7.2 Products offered
        • 12.1.7.2.1 Product launches and approvals
    • 12.1.8 VENUS CONCEPT
      • 12.1.8.1 Business overview
      • 12.1.8.2 Products offered
      • 12.1.8.3 Recent developments
        • 12.1.8.3.1 Product launches and approvals
        • 12.1.8.3.2 Deals
    • 12.1.9 SHARPLIGHT TECHNOLOGIES INC.
      • 12.1.9.1 Business overview
      • 12.1.9.2 Products offered
      • 12.1.9.3 Recent developments
        • 12.1.9.3.1 Product launches and approvals
    • 12.1.10 SCITON
      • 12.1.10.1 Business overview
      • 12.1.10.2 Products offered
      • 12.1.10.3 Recent developments
        • 12.1.10.3.1 Product launches and approvals
    • 12.1.11 CANDELA CORPORATION
      • 12.1.11.1 Business overview
      • 12.1.11.2 Products offered
      • 12.1.11.3 Recent developments
        • 12.1.11.3.1 Deals
    • 12.1.12 BTL INDUSTRIES
      • 12.1.12.1 Business overview
      • 12.1.12.2 Products offered
      • 12.1.12.3 Recent developments
        • 12.1.12.3.1 Product launches and approvals
        • 12.1.12.3.2 Deals
    • 12.1.13 FOTONA
      • 12.1.13.1 Business overview
      • 12.1.13.2 Products offered
      • 12.1.13.3 Recent developments
        • 12.1.13.3.1 Product launches and approvals
    • 12.1.14 GZ MTS ELECTRONICS CO., LTD.
      • 12.1.14.1 Business overview
      • 12.1.14.2 Products offered
    • 12.1.15 ROHRER AESTHETICS, INC.
      • 12.1.15.1 Business overview
      • 12.1.15.2 Products offered
      • 12.1.15.3 Recent developments
        • 12.1.15.3.1 Product launches and approvals
        • 12.1.15.3.2 Deals
  • 12.2 OTHER PLAYERS
    • 12.2.1 GBS INTERNATIONAL HOLDING LTD.
    • 12.2.2 SINCLAIR
    • 12.2.3 THERMI
    • 12.2.4 YOLO MEDICAL INC.
    • 12.2.5 DOMINION AESTHETIC TECHNOLOGIES, INC.
    • 12.2.6 ZIMMER MEDIZIN SYSTEME GMBH
    • 12.2.7 ERCHONIA CORPORATION
    • 12.2.8 CLASSYS INC.
    • 12.2.9 WON TECH CO., LTD.
    • 12.2.10 CELLSOUND AESTHETICS

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 BODY CONTOURING TREATMENTS MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 SURGICAL PROCEDURES PERFORMED ON MALE PATIENTS, 2021-2023
  • TABLE 3 NON-SURGICAL PROCEDURES PERFORMED ON MALE PATIENTS, 2021-2023
  • TABLE 4 AESTHETIC PLASTIC SURGEON FEES IN NORTH AMERICA, 2022 VS. 2023
  • TABLE 5 NUMBER OF SURGICAL PROCEDURES, BY COUNTRY, 2023
  • TABLE 6 NON-SURGICAL PROCEDURES, BY COUNTRY, 2023
  • TABLE 7 BODY CONTOURING TREATMENTS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 8 US: MEDICAL DEVICE CLASSIFICATION
  • TABLE 9 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 10 US: CLASSIFICATION OF BODY CONTOURING DEVICES
  • TABLE 11 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 12 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA)
  • TABLE 13 CHINA: CLASSIFICATION OF MEDICAL DEVICES
  • TABLE 14 REGULATORY APPROVALS FOR BODY CONTOURING DEVICES, BY COUNTRY
  • TABLE 15 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 MIDDLE EAST & AFRICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 MEDICAL REIMBURSEMENT CODES FOR BODY CONTOURING PROCEDURAL SERVICES IN US, 2023
  • TABLE 21 AVERAGE SELLING PRICE OF KEY PLAYERS, BY TECHNOLOGY, 2023 (USD)
  • TABLE 22 AVERAGE SELLING PRICE OF BODY CONTOURING DEVICES, BY REGION, 2021-2023 (USD)
  • TABLE 23 IMPORT DATA FOR BODY CONTOURING DEVICES (HS CODE 9018), BY COUNTRY, 2019-2023 (USD THOUSAND)
  • TABLE 24 IMPORT DATA FOR LASERS EXCLUDING LASER DIODES (HS CODE 901320), BY COUNTRY, 2019-2023 (USD THOUSAND)
  • TABLE 25 EXPORT DATA FOR BODY CONTOURING DEVICES (HS CODE 9018), BY COUNTRY, 2019-2023 (USD THOUSAND)
  • TABLE 26 EXPORT DATA FOR LASER EXCLUDING LASER DIODES (HS CODE 901320), BY COUNTRY, 2019-2023 (USD THOUSAND)
  • TABLE 27 INNOVATIONS AND PATENT REGISTRATIONS, JANUARY 2021-AUGUST 2024
  • TABLE 28 BODY CONTOURING TREATMENTS MARKET: PORTER'S FIVE FORCES
  • TABLE 29 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF BODY CONTOURING PRODUCTS
  • TABLE 30 INFLUENCE OF END USERS ON BUYING PROCESS, BY END USER
  • TABLE 31 BODY CONTOURING TREATMENTS MARKET: KEY CONFERENCES AND EVENTS, 2024-2025
  • TABLE 32 BRAND MAPPING OF THERMAL TECHNOLOGIES
  • TABLE 33 BRAND MAPPING OF NON-THERMAL TECHNOLOGIES
  • TABLE 34 BODY CONTOURING TREATMENTS MARKET: CURRENT UNMET NEEDS
  • TABLE 35 BODY CONTOURING TREATMENTS MARKET: INTENSITY OF CURRENT UNMET NEEDS
  • TABLE 36 BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 37 BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 38 BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 39 BODY CONTOURING TREATMENTS MARKET FOR INVASIVE RADIOFREQUENCY TECHNOLOGY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 40 BODY CONTOURING TREATMENTS MARKET FOR INVASIVE LASER TECHNOLOGY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 41 BODY CONTOURING TREATMENTS MARKET FOR INVASIVE ULTRASOUND TECHNOLOGY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 42 BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 43 BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 44 BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE RADIOFREQUENCY TECHNOLOGY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 45 BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE LASER TECHNOLOGY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 46 BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE ULTRASOUND TECHNOLOGY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 47 BODY CONTOURING TREATMENTS MARKET FOR CRYOLIPOLYSIS TECHNOLOGY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 48 BODY CONTOURING TREATMENTS MARKET FOR OTHER NON-INVASIVE TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 49 BODY CONTOURING TREATMENTS MARKET, BY GENDER, 2022-2029 (USD MILLION)
  • TABLE 50 BODY CONTOURING PROCEDURES IN FEMALE PATIENTS, 2022 VS. 2023
  • TABLE 51 BODY CONTOURING TREATMENTS MARKET FOR FEMALE PATIENTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 52 BODY CONTOURING PROCEDURES IN MALE PATIENTS, 2022 VS. 2023
  • TABLE 53 BODY CONTOURING TREATMENTS MARKET FOR MALE PATIENTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 54 BODY CONTOURING TREATMENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 55 TOP 5 COUNTRIES PERFORMING NON-SURGICAL FAT REDUCTION TREATMENTS, 2018-2023
  • TABLE 56 BODY CONTOURING TREATMENTS MARKET FOR NON-SURGICAL FAT REDUCTION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 57 BODY CONTOURING TREATMENTS MARKET FOR CELLULITE REDUCTION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 58 TOP 5 COUNTRIES PERFORMING LIPOSUCTION PROCEDURES, 2018-2023
  • TABLE 59 BODY CONTOURING TREATMENTS MARKET FOR LIPOSUCTION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 60 TOP 5 COUNTRIES PERFORMING ABDOMINOPLASTY TREATMENTS, 2018-2023
  • TABLE 61 BODY CONTOURING TREATMENTS MARKET FOR ABDOMINOPLASTY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 62 BODY CONTOURING TREATMENTS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 63 BODY CONTOURING TREATMENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 64 BODY CONTOURING TREATMENTS MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 65 BODY CONTOURING TREATMENTS MARKET FOR AESTHETIC CLINICS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 66 BODY CONTOURING TREATMENTS MARKET FOR MEDICAL SPAS & BEAUTY CENTERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 67 BODY CONTOURING TREATMENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 68 NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 69 NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 70 NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 71 NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 72 NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET, BY GENDER, 2022-2029 (USD MILLION)
  • TABLE 73 NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 74 NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 75 KEY MACROINDICATORS FOR NORTH AMERICA
  • TABLE 76 US: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 77 US: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 78 US: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 79 BODY CONTOURING PROCEDURES CONDUCTED IN US, 2020-2023
  • TABLE 80 CANADA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 81 CANADA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 82 CANADA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 83 EUROPE: BODY CONTOURING TREATMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 84 EUROPE: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 85 EUROPE: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 86 EUROPE: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 87 EUROPE: BODY CONTOURING TREATMENTS MARKET, BY GENDER, 2022-2029 (USD MILLION)
  • TABLE 88 EUROPE: BODY CONTOURING TREATMENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 89 EUROPE: BODY CONTOURING TREATMENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 90 KEY MACROINDICATORS FOR EUROPE
  • TABLE 91 BODY CONTOURING PROCEDURES CONDUCTED IN GERMANY, 2020-2023
  • TABLE 92 GERMANY: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 93 GERMANY: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 94 GERMANY: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 95 FRANCE: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 96 FRANCE: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 97 FRANCE: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 99 BODY CONTOURING PROCEDURES CONDUCTED IN UK, 2022-2023
  • TABLE 100 UK: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 101 UK: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 102 UK: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 103 BODY CONTOURING PROCEDURES CONDUCTED IN ITALY, 2020-2023
  • TABLE 104 ITALY: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 105 ITALY: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 106 ITALY: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 107 BODY CONTOURING PROCEDURES CONDUCTED IN SPAIN, 2021-2023
  • TABLE 108 SPAIN: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 109 SPAIN: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 110 SPAIN: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 111 REST OF EUROPE: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 112 REST OF EUROPE: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 113 REST OF EUROPE: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 114 ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET, BY GENDER, 2022-2029 (USD MILLION)
  • TABLE 118 ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 120 KEY MACROINDICATORS FOR ASIA PACIFIC
  • TABLE 121 BODY CONTOURING PROCEDURES CONDUCTED IN JAPAN, 2020-2022
  • TABLE 122 JAPAN: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 123 JAPAN: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 124 JAPAN: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 125 CHINA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 126 CHINA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 127 CHINA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 128 BODY CONTOURING PROCEDURES CONDUCTED IN INDIA, 2020-2023
  • TABLE 129 INDIA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 130 INDIA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 131 INDIA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 132 AUSTRALIA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 133 AUSTRALIA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 134 AUSTRALIA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 135 SOUTH KOREA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 136 SOUTH KOREA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 137 SOUTH KOREA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 138 REST OF ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 139 REST OF ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 140 REST OF ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 141 LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 142 LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 143 LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 144 LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET, BY GENDER, 2022-2029 (USD MILLION)
  • TABLE 145 LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 146 LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 147 KEY MACROINDICATORS FOR LATIN AMERICA
  • TABLE 148 BODY CONTOURING PROCEDURES CONDUCTED IN BRAZIL, 2020-2023
  • TABLE 149 BRAZIL: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 150 BRAZIL: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 151 BRAZIL: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 152 MEXICO: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 153 MEXICO: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 154 MEXICO: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 155 BODY CONTOURING PROCEDURES CONDUCTED IN ARGENTINA, 2020-2023
  • TABLE 156 REST OF LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 157 REST OF LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 158 REST OF LATIN AMERICA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 159 MIDDLE EAST & AFRICA: BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 160 MIDDLE EAST & AFRICA: BODY CONTOURING TREATMENTS MARKET FOR NON-INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 161 MIDDLE EAST & AFRICA: BODY CONTOURING TREATMENTS MARKET FOR INVASIVE TECHNOLOGIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 162 MIDDLE EAST & AFRICA: BODY CONTOURING TREATMENTS MARKET, BY GENDER, 2022-2029 (USD MILLION)
  • TABLE 163 MIDDLE EAST & AFRICA: BODY CONTOURING TREATMENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 164 MIDDLE EAST & AFRICA: BODY CONTOURING TREATMENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 165 KEY MACROINDICATORS FOR MIDDLE EAST & AFRICA
  • TABLE 166 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BODY CONTOURING TREATMENTS MARKET
  • TABLE 167 BODY CONTOURING TREATMENTS MARKET: DEGREE OF COMPETITION
  • TABLE 168 BODY CONTOURING TREATMENTS MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 169 BODY CONTOURING TREATMENTS MARKET: GENDER FOOTPRINT
  • TABLE 170 BODY CONTOURING TREATMENTS MARKET: APPLICATION FOOTPRINT
  • TABLE 171 BODY CONTOURING TREATMENTS MARKET: END-USER FOOTPRINT
  • TABLE 172 BODY CONTOURING TREATMENTS MARKET: REGION FOOTPRINT
  • TABLE 173 BODY CONTOURING TREATMENTS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 174 BODY CONTOURING TREATMENTS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • TABLE 175 BODY CONTOURING TREATMENTS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 176 BODY CONTOURING TREATMENTS MARKET: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 177 BODY CONTOURING TREATMENTS MARKET: EXPANSIONS, JANUARY 2021-AUGUST 2024
  • TABLE 178 ABBVIE INC.: COMPANY OVERVIEW
  • TABLE 179 ABBVIE INC.: PRODUCTS OFFERED
  • TABLE 180 ABBVIE INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 181 INMODE LTD.: COMPANY OVERVIEW
  • TABLE 182 INMODE LTD.: PRODUCTS OFFERED
  • TABLE 183 INMODE LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021- AUGUST 2024
  • TABLE 184 INMODE LTD.: DEALS, JANUARY 2021- AUGUST 2024
  • TABLE 185 BAUSCH HEALTH COMPANIES INC.: COMPANY OVERVIEW
  • TABLE 186 BAUSCH HEALTH COMPANIES INC.: PRODUCTS OFFERED
  • TABLE 187 BAUSCH HEALTH COMPANIES INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 188 CYNOSURE LUTRONIC: COMPANY OVERVIEW
  • TABLE 189 CYNOSURE LUTRONIC: PRODUCTS OFFERED
  • TABLE 190 CYNOSURE LUTRONIC: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 191 SISRAM MEDICAL LTD: COMPANY OVERVIEW
  • TABLE 192 SISRAM MEDICAL LTD: PRODUCTS OFFERED
  • TABLE 193 SISRAM MEDICAL LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021- AUGUST 2024
  • TABLE 194 SISRAM MEDICAL LTD: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 195 SISRAM MEDICAL LTD: EXPANSIONS, JANUARY 2021-AUGUST 2024
  • TABLE 196 CUTERA, INC.: COMPANY OVERVIEW
  • TABLE 197 CUTERA, INC.: PRODUCTS OFFERED
  • TABLE 198 CUTERA, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 199 EL.EN. S.P.A.: COMPANY OVERVIEW
  • TABLE 200 EL.EN. S.P.A.: PRODUCTS OFFERED
  • TABLE 201 EL.EN. S.P.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 202 VENUS CONCEPT: COMPANY OVERVIEW
  • TABLE 203 VENUS CONCEPT: PRODUCTS OFFERED
  • TABLE 204 VENUS CONCEPT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 205 VENUS CONCEPT: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 206 SHARPLIGHT TECHNOLOGIES INC.: COMPANY OVERVIEW
  • TABLE 207 SHARPLIGHT TECHNOLOGIES INC.: PRODUCTS OFFERED
  • TABLE 208 SHARPLIGHT TECHNOLOGIES INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 209 SCITON: COMPANY OVERVIEW
  • TABLE 210 SCITON: PRODUCTS OFFERED
  • TABLE 211 SCITON: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 212 CANDELA CORPORATION: COMPANY OVERVIEW
  • TABLE 213 CANDELA CORPORATION: PRODUCTS OFFERED
  • TABLE 214 CANDELA CORPORATION: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 215 BTL INDUSTRIES: COMPANY OVERVIEW
  • TABLE 216 BTL INDUSTRIES: PRODUCTS OFFERED
  • TABLE 217 BTL INDUSTRIES: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 218 BTL INDUSTRIES: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 219 FOTONA: COMPANY OVERVIEW
  • TABLE 220 FOTONA: PRODUCTS OFFERED
  • TABLE 221 FOTONA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 222 GZ MTS ELECTRONICS CO., LTD.: COMPANY OVERVIEW
  • TABLE 223 GZ MTS ELECTRONICS CO., LTD.: PRODUCTS OFFERED
  • TABLE 224 ROHRER AESTHETICS, INC.: COMPANY OVERVIEW
  • TABLE 225 ROHRER AESTHETICS, INC.: PRODUCTS OFFERED
  • TABLE 226 ROHRER AESTHETICS, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 227 ROHRER AESTHETICS, INC.: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 228 GBS INTERNATIONAL HOLDING LTD.: COMPANY OVERVIEW
  • TABLE 229 SINCLAIR: COMPANY OVERVIEW
  • TABLE 230 THERMI: COMPANY OVERVIEW
  • TABLE 231 YOLO MEDICAL INC.: COMPANY OVERVIEW
  • TABLE 232 DOMINION AESTHETIC TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 233 ZIMMER MEDIZINSYSTEME GMBH: COMPANY OVERVIEW
  • TABLE 234 ERCHONIA CORPORATION: COMPANY OVERVIEW
  • TABLE 235 CLASSYS INC.: COMPANY OVERVIEW
  • TABLE 236 WON TECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 237 CELLSOUND AESTHETICS: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 BODY CONTOURING TREATMENTS MARKET SEGMENTATION
  • FIGURE 2 BODY CONTOURING TREATMENTS MARKET: RESEARCH DESIGN
  • FIGURE 3 BODY CONTOURING TREATMENTS MARKET: KEY PRIMARY SOURCES (DEMAND AND SUPPLY-SIDE PARTICIPANTS)
  • FIGURE 4 BODY CONTOURING TREATMENTS: KEY INSIGHTS FROM PRIMARY INTERVIEWS
  • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 7 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 8 BODY CONTOURING TREATMENTS MARKET SIZE ESTIMATION: COMPANY REVENUE ESTIMATION
  • FIGURE 9 BODY CONTOURING TREATMENTS MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 11 DATA TRIANGULATION METHODOLOGY
  • FIGURE 12 BODY CONTOURING TREATMENTS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 BODY CONTOURING TREATMENTS MARKET, BY GENDER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 BODY CONTOURING TREATMENTS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 BODY CONTOURING TREATMENTS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 BODY CONTOURING TREATMENTS MARKET, BY REGION, 2024-2029 (CAGR)
  • FIGURE 17 GROWING DEMAND FOR MINIMALLY INVASIVE AND NON-INVASIVE PROCEDURES TO DRIVE MARKET
  • FIGURE 18 NON-INVASIVE TECHNOLOGIES SEGMENT TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
  • FIGURE 19 AESTHETIC CLINICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 20 ABDOMINOPLASTY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 21 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 22 BODY CONTOURING TREATMENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 23 NON-SURGICAL PROCEDURES PERFORMED GLOBALLY, 2023 VS. 2022
  • FIGURE 24 BODY CONTOURING TREATMENTS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 25 BODY CONTOURING TREATMENTS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 26 BODY CONTOURING TREATMENTS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 27 PREMARKET NOTIFICATION: 510(K) APPROVALS FOR MEDICAL DEVICES
  • FIGURE 28 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES
  • FIGURE 29 EUROPE: CE APPROVAL PROCESS FOR MEDICAL DEVICES
  • FIGURE 30 INVESTMENT AND FUNDING SCENARIO IN BODY CONTOURING TREATMENTS MARKET, 2019-2023 (USD MILLION)
  • FIGURE 31 NUMBER OF INVESTOR DEALS IN BODY CONTOURING TREATMENTS MARKET, BY KEY PLAYER, 2019-2023 (UNIT)
  • FIGURE 32 VALUE OF INVESTOR DEALS IN BODY CONTOURING TREATMENTS MARKET, BY KEY PLAYER, 2018-2022 (USD MILLION)
  • FIGURE 33 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY TECHNOLOGY, 2023
  • FIGURE 34 AVERAGE SELLING PRICE TREND OF BODY CONTOURING DEVICES, BY REGION, 2023
  • FIGURE 35 BODY CONTOURING TREATMENTS MARKET: PATENT ANALYSIS, 2013-2023
  • FIGURE 36 BODY CONTOURING TREATMENTS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 37 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BODY CONTOURING PRODUCTS
  • FIGURE 38 KEY BUYING CRITERIA, BY END USER
  • FIGURE 39 NEW REVENUE POCKETS FOR PLAYERS IN BODY CONTOURING TREATMENTS MARKET
  • FIGURE 40 MARKET POTENTIAL OF AI/GENERATIVE AI ON BODY CONTOURING TREATMENTS MARKET
  • FIGURE 41 NORTH AMERICA: BODY CONTOURING TREATMENTS MARKET SNAPSHOT
  • FIGURE 42 ASIA PACIFIC: BODY CONTOURING TREATMENTS MARKET SNAPSHOT
  • FIGURE 43 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN BODY CONTOURING TREATMENTS MARKET, 2019-2023
  • FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023
  • FIGURE 45 RANKING OF KEY PLAYERS IN BODY CONTOURING TREATMENTS MARKET, 2023
  • FIGURE 46 BODY CONTOURING TREATMENTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 47 BODY CONTOURING TREATMENTS MARKET: COMPANY FOOTPRINT
  • FIGURE 48 BODY CONTOURING TREATMENTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 50 EV/EBITDA OF KEY VENDORS
  • FIGURE 51 BODY CONTOURING TREATMENTS MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 52 ABBVIE INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 53 INMODE LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 54 BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 55 SISRAM MEDICAL LTD: COMPANY SNAPSHOT (2023)
  • FIGURE 56 CUTERA, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 57 EL.EN. S.P.A.: COMPANY SNAPSHOT (2023)
  • FIGURE 58 VENUS CONCEPT: COMPANY SNAPSHOT (2023)